Allogene Therapeutics (ALLO) Cash & Equivalents (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Cash & Equivalents data on file, last reported at $25.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 40.98% year-over-year to $25.1 million; the trailing twelve-month figure through Mar 2026 stood at $25.1 million (down 40.98% YoY), and the FY2025 full-year result was $51.7 million, down 31.28% from the prior year.
• Cash & Equivalents fell to $25.1 million in Q1 2026, from $51.7 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $161.5 million in Q2 2024 to a low of $11.8 million in Q4 2022.
• A 5-year average of $71.4 million and a median of $69.2 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents tumbled 89.85% in 2022 and jumped 567.82% in 2023, its largest moves.
• Tracing ALLO's Cash & Equivalents over 5 years: stood at $11.8 million in 2022, then jumped by 567.82% to $78.5 million in 2023, then dropped by 4.22% to $75.2 million in 2024, then plunged by 31.28% to $51.7 million in 2025, then plunged by 51.53% to $25.1 million in 2026.
• Business Quant data shows ALLO's Cash & Equivalents at $25.1 million in Q1 2026, $51.7 million in Q4 2025, and $37.8 million in Q3 2025.